Mersana Therapeutics to Participate in Guggenheim’s 6th Annual Biotechnology Conference
February 01 2024 - 8:00AM
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody-drug conjugates (ADCs) targeting cancers in
areas of high unmet medical need, today announced that members of
management will participate in a fireside chat at Guggenheim’s 6th
Annual Biotechnology Conference on February 8, 2024 at 11:30 a.m.
ET. A live webcast of this event will be available on the Investors
& Media section of Mersana’s website at www.mersana.com, and an
archived replay will be available for approximately 90 days
following the event.
About Mersana TherapeuticsMersana
Therapeutics is a clinical-stage biopharmaceutical company focused
on the development of novel antibody-drug conjugates (ADCs) and
driven by the knowledge that patients are waiting for new treatment
options. The company has developed proprietary cytotoxic
(Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms
that are generating a pipeline of wholly-owned and partnered
product candidates with the potential to treat a range of cancers.
Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4,
and XMT-2056, an Immunosynthen ADC targeting a novel epitope of
human epidermal growth factor receptor 2 (HER2). Mersana routinely
posts information that may be useful to investors on the “Investors
& Media” section of its website at www.mersana.com.
Contact:Jason Fredette
617-498-0020jason.fredette@mersana.com
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Apr 2024 to May 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From May 2023 to May 2024